Myeloproliferative Neoplasms

Treatment with pacritinib demonstrated a comparable safety profile to best available therapies for the treatment of patients with myelofibrosis.

Shared insight on the respective roles of fedratinib and pacritinib in patients diagnosed with myelofibrosis.

Expert perspectives on the role of ruxolitinib in patients who require systemic therapy for myelofibrosis.

A brief review of the historical use of systemic therapy in patients who present with myelofibrosis.

Stephen Oh, MD, PhD, highlights the role of transplant in myelofibrosis before Ruben Mesa, MD, discusses factors in selecting systemic therapy.

The FDA has placed a partial clinical hold on a phase 1 trial investigating FHD-286 as a treatment for patients with relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome.

Expert Pankit Vachhani, MD, breaks down best practices in observation and dictates when it is best to initiated therapy for myelofibrosis.

Experts focus on how best to risk stratify and stage myelofibrosis using appropriate diagnostic tools and workup.

Reflections on the predominant challenges one may face while making a differential diagnosis of myelofibrosis.

Shared insight on the differential diagnosis of myelofibrosis, including advice for identifying primary versus secondary disease.

A brief discussion on the role of ruxolitinib in the management of polycythemia vera, followed by a review of goals of therapy in this setting.

Pankit Vachhani, MD, provides a comprehensive overview of approved agents used to manage patients with polycythemia vera.

Srdan Verstovsek, MD, PhD, discusses the future of ALK2 inhibitors in myelofibrosis.

Ruben A. Mesa, MD, discusses the future of JAK inhibitor therapy in myelofibrosis.

Srdan Verstovsek, MD, PhD, discusses addressing anemia in patients with myelofibrosis.

Shared insight on making a differential diagnosis of polycythemia vera and properly risk-stratifying patients who present with this disease.

Expert Stephen Oh, MD, PhD, provides a broad overview of the myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis.

Srdan Verstovsek, MD, PhD, discusses the preliminary results of the MOMENTUM study and the potential for ALK2 inhibitor success in the larger anemia treatment landscape.

Srdan Verstovsek, MD, PhD, discusses the mechanisms of action of momelotinib in myelofibrosis.

Ruben Mesa, MD, Jamile M. Shammo, MD, FASCP, FACP, Angela G. Fleischman, MD, PhD, and Stephen T. Oh, MD, PhD discuss the emerging treatment landscape in myelofibrosis.

Physical function-related symptoms were prominent in the symptom burden of adult patients with myelofibrosis and moderate or severe thrombocytopenia, according to a retrospective analysis of the phase 3 PERSIST-2 study.

Navitoclax plus ruxolitinib produced an improvement in bone marrow fibrosis and a reduction in variant allele frequency in patients with myelofibrosis who progressed on or had suboptimal response with prior ruxolitinib monotherapy.

The FDA has lifted a partial clinical hold that had been placed on studies examining magrolimab in combination with azacitidine following a review of comprehensive safety data collected from each trial.

Ann S. LaCasce, MD, MMSc, discusses updates in lymphoma, myelofibrosis, and chronic lymphocytic leukemia.

Jacqueline S. Garcia, MD, discusses the results of the phase 2 REFINE trial in patients with myelofibrosis.